BioNTech, DualityBio Say DYNASTY-Breast02 Phase 3 Trial Met Primary Endpoint, Showing Statistically Significant Yet Modest PFS Improvement For Trastuzumab Pamirtecan; Higher ILD Rate, OS Data Not Mature, Benefit Limited

뉴스 본문을 불러오고 있어요.

BioNTech, DualityBio Say DYNASTY-Breast02 Phase 3 Trial Met Primary Endpoint, Showing Statistically Significant Yet Modest PFS Improvement For Trastuzumab Pamirtecan; Higher ILD Rate, OS Data Not Mature, Benefit Limited | 웨이프 WAPE

BioNTech, DualityBio Say DYNASTY-Breast02 Phase 3 Trial Met Primary Endpoint, Showing Statistically Significant Yet Modest PFS Improvement For Trastuzumab Pamirtecan; Higher ILD Rate, OS Data Not Mature, Benefit Limited

기사 요약

관련 종목

댓글 —